Flow Cytometric Immunophenotyping Test for Staging/Monitoring Neuroblastoma Patients

Clinical Cytometry

Volumn 50, Issue 6, 2002, Pages 298-304

  Warzynski, Michael J ^a,c   Graham, David M ^a   Axtell, Richard A ^a   Higgins, James V ^a   Hammers, Yuki A ^b  

^a Spectrum Health ^*  (United States)

^b CHILDREN S HOSPITAL   (United States)

^c Flow Cytometry Lab   (United States)

Author keywords

CD56; CD81; Flow cytometry; Ganglioside; GD2; Neuroblastoma

Indexed keywords

CD45 ANTIGEN; CD56 ANTIGEN; CELL ANTIGEN; GANGLIOSIDE GD2; NEURON SPECIFIC ENOLASE;

ARTICLE; BONE MARROW BIOPSY; CANCER STAGING; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CHILD; CONTROLLED STUDY; CYTOLYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MELANOMA; NATURAL KILLER CELL; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PRIORITY JOURNAL; SMALL CELL CARCINOMA; TUMOR CELL; VALIDATION PROCESS;

FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; NEOPLASM STAGING; NEUROBLASTOMA;

EID: 0345530005     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.10159     Document Type: Article

References (33)

1. nd edition, Atlanta: American Cancer Society; 1995. p 535-537.
2. Lee WS, Chung WS, Chang CD, Hyunbh BK. Hematopathology no. HP 96-3 (HP-13) check sample, volume 2 #3. Chicago: American Society of Clinical Pathologists; 1996. p 33-47.
3. Kelly DR, Joshi VV. Neuroblastoma and related tumors. In: Parham DM, editor. Neoplasia: morphology and biology. Philadelphia: Lippincott-Raven; 1996. p 105-152.
4. Shimada H, Chaten J, Newton WA Jr, Sachs N, Hamondi AB, Chiba T, Marsden HB, Misugi K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastoma. J Clin Oncol 1988;14: 1874-1881.
5. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-1881.
6. Marshall T, Rutledge JC. Flow cytometry DNA applications in pediatric tumor pathology. Pediatr Dev Pathol 2000;3:314-334.
7. Warzynski MJ, Graham DM, Axtell RA, Higgins JV, Hammers YA. Flow cytometry immunophenotyping test for staging/monitoring neuroblastoma patients [poster 41]. Cytometry 2000;42:324-325.
8. Kussick S, Wood B, Li Y. Using antibodies to CD56 and CD45 to identify nonhematopoietic small cell tumors by flow cytometry. Am J Clin Pathol 2001;116:279.
9. Shaw S, CD Guide. In: Kishimoto T, Kikutani H, et al., editors. Leucocyte typing VI white cell differentiation antigens. New York: Garland Publishing Inc., 1996. p 1109-1220.
10. Nagai J, Kigasawa H, Tomioka K, Koga N, Nishihira H, Nagao T. Immunohistochemical detection of bone marrow invasive neuroblastoma cells. Eur J Haematol 1994;53:74-77.
11. Ozawa H, Kotani M, Kawashima I, Tai T. Generation of one set of monoclonal antibodies specific for b-pathway ganglio-series gangliosides. Biochim Biophys Acta 1992;1123:104-190.
12. D2 ganglioside in human neuroblastoma. In: Pochedly C, editor. Neuroblastoma: tumor biology and therapy. Boca Raton, FL: CRC; 1990. p 93-109.
13. D2 specific monoclonal antibodies. J Clin Oncol 1986;4:363-369.
14. Kawashima I, Tada N, Fujimuri T, Tai T. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro. J Biochem 1990;108:109-115.
15. Chen RL, Reynolds CP, Seeger RC. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunol Immunother 2000;48:603-612.
16. Cheung NV, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PE. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985;45:2642-2649.
17. D2 ganglioside by untreated primary human neuroblastomas. Cancer Research 1986; 46:440-443.
18. Seeger RC, Reynolds P, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a children's cancer group study. J Clin Oncol 2000;18:4067-4076.
19. Rogers DW, Treleaven JG, Kemshead JT, Pritchard J. Monoclonal antibodies for detecting bone marrow invasion by neuroblastoma. J Clin Pathol 1989;42:422-426.
20. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324:219-226.
21. Cohn SL, Moss TJ, Hoover M, Katzenstein HM, Haut PR, Morgan ER, Green AA, Kletzel M. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. Bone Marrow Transplant 1997;20:543-551.
22. Nagai JI, Ishida Y, Koga N, Tanaka Y, Ohnuma K, Toyoaa Y, Katoh A, Haynbuchi Y, Kigasawa H. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry. J Pediatr Hematol Oncol 2000;22:20-26.
23. Komada Y, Zhang XL, Zhou YW, Inaba H, Deguchi T, Azuma E, Sakurai M. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma. Cancer 1998; 82:591-599.
24. Miyajima Y, Kato K, Numata SI, Kudo K, Horige K. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 1995;75:2757-2761.
25. Mito H, Kuzumaki N, Uchino J, Kobayuashi R, Shikano T, Ishikawa Y, Matsumoto S. Detection of tyrosine hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcription-polmerase chain reaction. Eur J Cancer 1991;27:762-765.
26. Mattano LA Jr, Moss TJ, Emerson SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 1992;52:4701-4705.
27. Reynolds CP, Moss TJ, Seeger RC, Black, AT, Woody JN. Sensitive detection of neuroblastoma cells in bone marrow for monitoring the efficacy of marrow purging procedures. In: Evans AE, D'Angio G, Seeger RC, editors. Advances in neuroblastoma research. New York: Liss; 1985. p 425-441.
28. Dicaro A, Bostrom B, Moss TJ, Neglia J, Ramsay NK, Smith J, Lasky LC. Autologous peripheral blood cell transplantation in the treatment of advanced neuroblastoma. Am J Pediatr Hematol Oncol 1994;16:200-206.
29. Sugimot T, Taysumi E, Kemshead JT, Helson L, Green AA, Minowada J. Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia lymphoma cell lines by a panel of 38 monoclonal antibodies. J Natl Cancer Inst 1984;73:51-57.
30. Komada Y, Azuma E, Kamiya H, Sakurai M. Phenotypic profile of human neuroblastoma cell lines: association with morphological characteristics. Br J Cancer 1986;54:711-715.
31. Donner L, Triche TJ, Israel MA, Seeger RC, Reynolds CP. A panel of monoclonal antibodies which discriminate neuroblastoma from Ewing's sarcoma, rhabdomyosarcoma, neuroepithelioma, and hematopoietic malignancies. In: Evans AE, D'Angio G, Seeger RC, editors. Advances in neuroblastoma research. New York: Liss; 1985. p 347-366.
32. Mechtersheimer G, Barth T, Ludwig R, Staudter M, Moller P. Differential expression of leukocyte differentiation antigens in small round blue cell sarcomas. Cancer 1993;71:237-248.
33. Oren R, Takahashi S, Doss C, Levy R, Levy S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol 1990;10:4007-4015.